Objective: Despite the existence of numerous case series, no evidenced-based medical management for atypical fractures associated with bisphosphonate (BP) treatment has been established.

Design: We report the outcome of teriparatide (TRP) administration followed by strontium ranelate (SR) in a woman with a complete and an incomplete contralateral atypical fracture of the femoral diaphysis (AFF) associated with BP treatment. The spontaneous complete AFF was managed with intramedullary nailing, discontinuation of BP and initiation TRP.

Results: Eleven months later, she suffered a contralateral incomplete AFF. At the completion of the TRP treatment, she had only slight discomfort in the femur with the incomplete AFF. BMD testing revealed increase of 7.61% at the lumbar spine (LS) and 0.8% at the hip. Following TRP, 1-year SR treatment resulted in further BMD increase of 9.2% at the LS and 1.4% in the hip, while she does not report any pain. Bone markers remain within the normal range.

Conclusion: Our case indicates that sequential therapy with TRP and SR in cases of AFF might be a rational treatment option. However, there is a need for additional information concerning the effect of TRP and SR, given alone or sequentially, in these patients in order to incorporate these drugs into the management of AFF.

Download full-text PDF

Source
http://dx.doi.org/10.14310/horm.2002.1448DOI Listing

Publication Analysis

Top Keywords

strontium ranelate
8
incomplete aff
8
aff
6
treatment
5
trp
5
sequential treatment
4
treatment teriparatide
4
teriparatide strontium
4
ranelate postmenopausal
4
postmenopausal woman
4

Similar Publications

Article Synopsis
  • Pregnancy- and lactation-associated osteoporosis (PLO) is a rare condition impacting women postpartum, exemplified by a case of a 29-year-old with severe back pain due to vertebral fractures.
  • Diagnosis involves ruling out other causes of osteoporosis, with treatment typically including calcium and vitamin D supplements alongside lactation suppression; however, pain may persist even after treatment.
  • The condition remains poorly understood, with potential causes including genetic factors and calcium metabolism changes, highlighting the need for early diagnosis and personalized treatment strategies for better patient outcomes.
View Article and Find Full Text PDF

Repairing effect of magnesium oxychloride cement modified by γ-polyglutamic acid and chitosan in osteoporotic bone defect.

Int J Biol Macromol

December 2024

Henan Key Laboratory of Materials on Deep-Earth Engineering, School of Materials Science and Engineering, Henan Polytechnic University, Jiaozuo, China. Electronic address:

Magnesium oxychloride cement (MOC) has the advantage of high early strength. However, it has the defect of poor water resistance. Considering this performance, we use γ-polyglutamic acid (γ-PGA) and chitosan (CS) to modify MOC.

View Article and Find Full Text PDF

Multiple vertebral fractures after antiosteoporotic medications discontinuation: A comparative study to evaluate the potential rebound effect of denosumab.

Bone

January 2025

Pharmacoepidemiology and Pharmacovigilance Department, Spanish Agency of Medicines and Medical Devices (AEMPS), Calle Campezo n° 1, Edificio 8, 28022 Madrid, Spain. Electronic address:

Article Synopsis
  • Discontinuation of anti-osteoporotic medications, particularly Prolia® (denosumab), significantly increases the risk of multiple vertebral fractures (MVF) due to a rapid rise in bone turnover markers and loss of bone mineral density.
  • A study using data from the Public Health System in Spain analyzed patients who had recently started various anti-osteoporotic medications, finding a strong association between denosumab discontinuation and a 2.82 times higher risk of MVF compared to those still on the medication.
  • The risk of MVF after stopping denosumab was especially high within the first 3 to 9 months after discontinuation, increasing further after longer cumulative use of
View Article and Find Full Text PDF

Osteoarthritis year in review 2024: Imaging.

Osteoarthritis Cartilage

January 2025

Department of Radiology, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA, USA; Department of Radiology, Boston VA Healthcare System, West Roxbury, MA, USA.

Objective: To review recent literature evidence describing imaging of osteoarthritis (OA) and to identify the current trends in research on OA imaging.

Method: This is a narrative review of publications in English, published between April, 2023, and March, 2024. A Pubmed search was conducted using the following search terms: osteoarthritis/OA, radiography, ultrasound/US, computed tomography/CT, magnetic resonance imaging/MRI, DXA/DEXA, and artificial intelligence/AI/deep learning.

View Article and Find Full Text PDF

Alleviating rheumatoid arthritis with a photo-pharmacotherapeutic glycan-integrated nanogel complex for advanced percutaneous delivery.

J Nanobiotechnology

October 2024

Graduate Institute of Biomedical Materials and Tissue Engineering, Graduate Institute of Nanomedicine and Medical Engineering, College of Biomedical Engineering, Taipei Medical University, New Taipei City, Taiwan.

The prospective of percutaneous drug delivery (PDD) mechanisms to address the limitations of oral and injectable treatment for rheumatoid arthritis (RA) is increasing. These limitations encompass inadequate compliance among patients and acute gastrointestinal side effects. However, the skin's intrinsic layer can frequently hinder the percutaneous dispersion of RA medications, thus mitigating the efficiency of drug delivery.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!